CN104853758A - 肺部疾病的治疗 - Google Patents

肺部疾病的治疗 Download PDF

Info

Publication number
CN104853758A
CN104853758A CN201380061734.4A CN201380061734A CN104853758A CN 104853758 A CN104853758 A CN 104853758A CN 201380061734 A CN201380061734 A CN 201380061734A CN 104853758 A CN104853758 A CN 104853758A
Authority
CN
China
Prior art keywords
compound
lung
pulmonary
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380061734.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·普鲁赞斯基
卢西亚诺·阿多里尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingte Saipute Pharmaceuticals Co
Original Assignee
Yingte Saipute Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49753520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104853758(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yingte Saipute Pharmaceuticals Co filed Critical Yingte Saipute Pharmaceuticals Co
Publication of CN104853758A publication Critical patent/CN104853758A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380061734.4A 2012-11-28 2013-11-26 肺部疾病的治疗 Pending CN104853758A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730749P 2012-11-28 2012-11-28
US61/730,749 2012-11-28
PCT/US2013/072038 WO2014085474A1 (en) 2012-11-28 2013-11-26 Treatment of pulmonary disease

Publications (1)

Publication Number Publication Date
CN104853758A true CN104853758A (zh) 2015-08-19

Family

ID=49753520

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061734.4A Pending CN104853758A (zh) 2012-11-28 2013-11-26 肺部疾病的治疗

Country Status (19)

Country Link
US (3) US20140148428A1 (enExample)
EP (1) EP2925328A1 (enExample)
JP (1) JP6270171B2 (enExample)
KR (1) KR102106186B1 (enExample)
CN (1) CN104853758A (enExample)
AU (1) AU2013352288B2 (enExample)
BR (1) BR112015012312A2 (enExample)
CA (1) CA2891348C (enExample)
CL (1) CL2015001442A1 (enExample)
HK (1) HK1211844A1 (enExample)
IL (1) IL239025B (enExample)
MX (1) MX2015006710A (enExample)
MY (1) MY170802A (enExample)
NZ (1) NZ708501A (enExample)
PH (1) PH12015501108A1 (enExample)
RU (1) RU2693382C2 (enExample)
SG (1) SG11201503697TA (enExample)
TW (1) TWI636786B (enExample)
WO (1) WO2014085474A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085597A (zh) * 2015-08-28 2015-11-25 成都百裕科技制药有限公司 一种无定型奥贝胆酸的制备方法
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
CN106046095A (zh) * 2016-06-06 2016-10-26 南京理工大学 奥贝胆酸的合成方法
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106589039A (zh) * 2015-10-15 2017-04-26 苏州朗科生物技术有限公司 一种奥贝胆酸的制备方法及相关化合物
CN109071452A (zh) * 2016-04-13 2018-12-21 英特塞普特医药品公司 治疗癌症的方法
CN109415405A (zh) * 2016-06-01 2019-03-01 雷迪博士实验室有限公司 制备奥贝胆酸的方法
CN113318114A (zh) * 2020-02-28 2021-08-31 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202601B2 (en) 2013-11-22 2019-02-12 Mina Therapeutics Limited C/EBPα short activating RNA compositions and methods of use
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
WO2016079518A1 (en) * 2014-11-19 2016-05-26 Dextra Laboratories Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
CN107108688B (zh) * 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
TWI688571B (zh) * 2014-11-19 2020-03-21 英商Ｎｚｐ英國有限公司 化合物（四）
PL3221331T3 (pl) * 2014-11-19 2020-03-31 NZP UK Limited Steroidy, 6-alkilo-7-hydroksy-4-en-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
US11072631B2 (en) * 2015-09-24 2021-07-27 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
UA123948C2 (uk) * 2015-10-07 2021-06-30 Інтерсепт Фармасьютікалз, Інк. Модулятори фарнезоїдного х-рецептора
CN106668027A (zh) * 2015-11-05 2017-05-17 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸药物组合物及其制备方法
CN108779141A (zh) 2016-02-10 2018-11-09 雷迪博士实验室有限公司 奥贝胆酸的胺盐
JPWO2017170858A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
KR20190057108A (ko) * 2016-09-30 2019-05-27 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체의 결정형
CN108117579A (zh) * 2016-11-29 2018-06-05 昆明积大制药股份有限公司 奥贝胆酸及其中间体的制备方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
WO2019048631A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
WO2019085963A1 (zh) * 2017-11-02 2019-05-09 正大天晴药业集团股份有限公司 一种胆酸类化合物的制备方法
BR112021000964A2 (pt) 2018-07-25 2021-04-20 Novartis Ag inibidores do inflamassoma de nlrp3
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
BR112022017039A2 (pt) 2020-02-28 2022-11-16 Kallyope Inc Agonistas de gpr40
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
WO2002072598A1 (en) * 2001-03-12 2002-09-19 Roberto Pellicciari Steroids as agonists for fxr
WO2005089316A2 (en) * 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
WO2008002573A2 (en) * 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2010014836A2 (en) * 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2011022838A1 (en) * 2009-08-25 2011-03-03 British Columbia Cancer Agency Branch Polyhydroxylated bile acids for treatment of biliary disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
IT1203660B (it) 1982-10-08 1989-02-15 Glaxo Group Ltd Dispositivi per somministrare farmaci a pazienti e confezione di blister per essi
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
AU698364B2 (en) 1995-03-10 1998-10-29 Minnesota Mining And Manufacturing Company Aerosol valves
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US20070015796A1 (en) * 2003-09-26 2007-01-18 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
MX2008015923A (es) * 2006-06-29 2009-01-13 Hoffmann La Roche Derivados de bencimidazol, metodo para su produccion, su uso como agonistas fxr y preparaciones farmaceuticas que los contienen.
EP3150620B1 (en) * 2008-11-19 2020-01-08 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
EP2379081B1 (en) * 2008-12-19 2013-03-20 Royal College of Surgeons in Ireland Treatment of diarrhoea
US9416151B2 (en) * 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CA2877122C (en) * 2012-06-19 2020-04-28 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
WO2002072598A1 (en) * 2001-03-12 2002-09-19 Roberto Pellicciari Steroids as agonists for fxr
WO2005089316A2 (en) * 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
WO2008002573A2 (en) * 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2010014836A2 (en) * 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2011022838A1 (en) * 2009-08-25 2011-03-03 British Columbia Cancer Agency Branch Polyhydroxylated bile acids for treatment of biliary disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FENGTIAN HE等: "Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells", 《CIRC RES.》 *
LISHENG ZHANG等: "FXR Protects Lung from Lipopolysaccharide-Induced Acute Injury", 《MOL ENDOCRINOL》 *
NAZZARENO GALIE等: "The endothelin system in pulmonary arterial hypertension", 《CARDIOVASCULAR RESEARCH》 *
ROBERTO PELLICCIARI等: "6α-Ethyl-Chenodeoxycholic Acid(6-ECDCA),a potent and selective FXR Agonist Endowed with Anticholestatic Activity", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
周川: "牛磺鹅去氧胆酸抗小鼠肺纤维化作用的研究", 《万方数据》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085597A (zh) * 2015-08-28 2015-11-25 成都百裕科技制药有限公司 一种无定型奥贝胆酸的制备方法
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106589039A (zh) * 2015-10-15 2017-04-26 苏州朗科生物技术有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
CN109071452A (zh) * 2016-04-13 2018-12-21 英特塞普特医药品公司 治疗癌症的方法
CN109415405A (zh) * 2016-06-01 2019-03-01 雷迪博士实验室有限公司 制备奥贝胆酸的方法
CN106046095A (zh) * 2016-06-06 2016-10-26 南京理工大学 奥贝胆酸的合成方法
CN106046095B (zh) * 2016-06-06 2017-02-22 南京理工大学 奥贝胆酸的合成方法
CN113318114A (zh) * 2020-02-28 2021-08-31 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途
WO2021170073A1 (zh) * 2020-02-28 2021-09-02 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途

Also Published As

Publication number Publication date
TW201434469A (zh) 2014-09-16
AU2013352288B2 (en) 2017-11-23
TWI636786B (zh) 2018-10-01
BR112015012312A2 (pt) 2017-07-11
JP6270171B2 (ja) 2018-01-31
PH12015501108B1 (en) 2015-08-17
MX2015006710A (es) 2016-01-15
HK1211844A1 (en) 2016-06-03
PH12015501108A1 (en) 2015-08-17
CA2891348A1 (en) 2014-06-05
CL2015001442A1 (es) 2015-08-28
US20160213689A1 (en) 2016-07-28
NZ708501A (en) 2019-03-29
IL239025A0 (en) 2015-07-30
US20140148428A1 (en) 2014-05-29
WO2014085474A1 (en) 2014-06-05
US20180064729A1 (en) 2018-03-08
KR20150089052A (ko) 2015-08-04
AU2013352288A1 (en) 2015-06-04
KR102106186B1 (ko) 2020-05-04
IL239025B (en) 2021-04-29
JP2016500111A (ja) 2016-01-07
MY170802A (en) 2019-08-28
RU2015122027A (ru) 2017-01-10
CA2891348C (en) 2020-04-28
EP2925328A1 (en) 2015-10-07
RU2693382C2 (ru) 2019-07-02
SG11201503697TA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
CN104853758A (zh) 肺部疾病的治疗
EP1939175B1 (en) Sulfonamide derivative having pgd2 receptor antagonistic activity
CN102892765B (zh) 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的环己胺衍生物
AU2012333986B2 (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
US10173985B2 (en) Aminoindazole derivatives as sodium channel inhibitors
KR20150123245A (ko) β2 아드레날린성 수용체 아고니스트 및 M3 무스카린성 수용체 안타고니스트 활성 모두를 갖는 ２-아미노-１-히드록시에틸-８-히드록시퀴놀린-２（１H）-온 유도체의 염
CA2815029A1 (en) Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
EP2776426A1 (en) New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities
TW201010707A (en) Corticosteroid linked beta-agonist compounds for use in therapy
CA3043132A1 (en) Benzodiazolium compounds as enac inhibitors
EP2548863A1 (en) New CRTh2 antagonists.
KR20190091455A (ko) Nrf2 화합물
US20250161283A1 (en) Use of indazole compound for treating psoriasis
CN110753688A (zh) 用于治疗呼吸系统疾病的化合物
CN102834406A (zh) 作为糖皮质激素受体激动剂的新的[3.2-c]杂芳基甾体、其组合物和用途
CA2750796A1 (en) 5-ht4 inhibitors for treating airway diseases, in particular asthma
WO2022175425A1 (en) Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
NZ624784B2 (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
HK1197241B (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211844

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150819

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211844

Country of ref document: HK